Scott Solomon

1.5k total citations · 1 hit paper
40 papers, 425 citations indexed

About

Scott Solomon is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Scott Solomon has authored 40 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cardiology and Cardiovascular Medicine, 6 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Scott Solomon's work include Heart Failure Treatment and Management (20 papers), Cardiovascular Function and Risk Factors (18 papers) and Cardiac pacing and defibrillation studies (5 papers). Scott Solomon is often cited by papers focused on Heart Failure Treatment and Management (20 papers), Cardiovascular Function and Risk Factors (18 papers) and Cardiac pacing and defibrillation studies (5 papers). Scott Solomon collaborates with scholars based in United States, United Kingdom and Italy. Scott Solomon's co-authors include Faı̈ez Zannad, Patrick Rossignol, Adrian F. Hernandez, Michael Böhm, Thomas Franz, Stephen J. Greene, Aldo P. Maggioni, Gregg C. Fonarow, Kevin L. Sack and Daniel Burkhoff and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Investigation.

In The Last Decade

Scott Solomon

22 papers receiving 417 citations

Hit Papers

Heart failure drug treatment 2019 2026 2021 2023 2019 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Heart failure drug treatment
    2019 246 citations Adrian F. Hernandez, Scott Solomon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Solomon United States 7 263 77 69 52 50 40 425
Maria Prastaro Italy 11 368 1.4× 74 1.0× 112 1.6× 55 1.1× 62 1.2× 33 563
Lucia Ilaria Birtolo Italy 11 374 1.4× 155 2.0× 128 1.9× 63 1.2× 45 0.9× 45 648
Evelyn Santiago‐Vacas Spain 14 380 1.4× 118 1.5× 85 1.2× 100 1.9× 79 1.6× 45 571
Ivan Milinković Serbia 12 430 1.6× 76 1.0× 55 0.8× 89 1.7× 60 1.2× 26 537
Roberto Spoladore Italy 15 473 1.8× 84 1.1× 101 1.5× 35 0.7× 31 0.6× 58 625
Isabella Evangelista Italy 12 231 0.9× 73 0.9× 92 1.3× 64 1.2× 65 1.3× 23 407
Georgios Efstratiadis Greece 13 178 0.7× 114 1.5× 60 0.9× 53 1.0× 69 1.4× 25 500
Yingying Li China 11 204 0.8× 50 0.6× 83 1.2× 60 1.2× 24 0.5× 32 384
Javier E. Banchs United States 14 459 1.7× 84 1.1× 60 0.9× 18 0.3× 42 0.8× 43 600
Nikolaos Stalikas Greece 12 221 0.8× 61 0.8× 55 0.8× 96 1.8× 18 0.4× 36 387

Countries citing papers authored by Scott Solomon

Since Specialization
Citations

This map shows the geographic impact of Scott Solomon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Solomon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Solomon more than expected).

Fields of papers citing papers by Scott Solomon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Solomon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Solomon. The network helps show where Scott Solomon may publish in the future.

Co-authorship network of co-authors of Scott Solomon

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Solomon. A scholar is included among the top collaborators of Scott Solomon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Solomon. Scott Solomon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kondo, Toru, Pardeep S. Jhund, Inder S. Anand, et al.. (2025). Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF. JACC Heart Failure. 13(6). 927–939. 2 indexed citations
2.
Pabón, Maria, John W. Ostrominski, Brian Claggett, et al.. (2025). PROGNOSTIC IMPACT OF HEPATORENAL DYSFUNCTION AND CARDIOVASCULAR-KIDNEYMETABOLIC MULTIMORBIDITY IN HEART FAILURE: A PARTICIPANT-LEVEL POOLED ANALYSIS OF THE PARADIGM-HF AND PARAGON-HF TRIALS. Journal of the American College of Cardiology. 85(12). 1339–1339.
3.
Matsumoto, Shingo, Jawad H. Butt, Kieran F. Docherty, et al.. (2025). Obesity, aldosterone, and natriuretic peptides in patients with heart failure and reduced ejection fraction. Cardiovascular Research. 122(1). 14–18.
4.
Gunn, Alexander, Derek D. Cyr, Adrian F. Hernandez, et al.. (2025). Sacubitril/Valsartan Versus Valsartan Initiation in Patients Naïve to Renin–angiotensin System Inhibitors: Insights from PARAGLIDE-HF. European Journal of Heart Failure. 27(8). 1418–1425. 1 indexed citations
5.
Miao, Zi Michael, Brian Claggett, Pablo García‐Pavía, et al.. (2025). Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial. European Journal of Heart Failure. 27(12). 2971–2978.
6.
Lassen, Mats Christian Højbjerg, John W. Ostrominski, Brian Claggett, et al.. (2025). Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction. JACC Heart Failure. 13(8). 102498–102498. 2 indexed citations
7.
Fontana, Marianna, Muthiah Vaduganathan, Yasuhiro Hamatani, et al.. (2025). Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis. Journal of the American College of Cardiology. 87(5). 522–529.
8.
Heidecker, Bettina, Peter Libby, Vassilios S. Vassiliou, et al.. (2025). Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement. European Heart Journal. 46(36). 3518–3531. 9 indexed citations
9.
Chimura, Misato, Kieran F. Docherty, Pardeep S. Jhund, et al.. (2025). Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. European Heart Journal. 47(1). 69–79.
10.
Agarwal, Rajiv, et al.. (2025). MECHANISMS OF CARDIOVASCULAR BENEFIT WITH FINERENONE—A CAUSAL MEDIATION ANALYSIS OF THE JOINT EFFECTS OF SYSTOLIC BLOOD PRESSURE AND ALBUMINURIA REDUCTION. Journal of the American College of Cardiology. 85(12). 424–424. 1 indexed citations
11.
Ostrominski, John W., Brian Claggett, Akshay S. Desai, et al.. (2025). EFFICACY AND SAFETY OF FINERENONE ACROSS THE SPECTRUM OF KIDNEY RISK IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION. Journal of the American College of Cardiology. 85(12). 1167–1167.
12.
Foà, Alberto, Maria Pabón, Eugene Braunwald, et al.. (2024). Mortality After High-Risk Myocardial Infarction Over the Last 20 Years: Insights from the VALIANT and PARADISE-MI Trials. European Journal of Heart Failure. 27(3). 589–597. 3 indexed citations
13.
Lassen, Mats Christian Højbjerg, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.. (2024). Electronic Nudge Letters to Increase Influenza Vaccination Uptake in Younger and Middle-Aged Individuals With Diabetes. JACC Advances. 3(12). 101391–101391.
14.
Lu, Henri, Brian Claggett, Milton Packer, et al.. (2024). Visit-to-Visit Changes in Heart Rate in Heart Failure: A Pooled Participant-Level Analysis of the PARADIGM-HF and PARAGON-HF Trials. European Journal of Heart Failure. 27(1). 60–68.
15.
Gupta, Shruti, Jawad H. Butt, Atefeh Talebi, et al.. (2024). Effects of Sacubitril/Valsartan According to Background Beta-Blocker Therapy in Patients with Heart Failure and Reduced Ejection Fraction: Insights from PARADIGM-HF. European Journal of Heart Failure. 27(5). 779–787.
16.
Omar, Alaa Mabrouk Salem, Sean Murphy, G. Michael Felker, et al.. (2023). Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study. Journal of Cardiac Failure. 30(5). 653–665.
17.
Docherty, Kieran F., Brian Claggett, Rafael Díaz, et al.. (2022). THE EFFECT OF OMECAMTIV MECARBIL IN HOSPITALIZED PATIENTS AS COMPARED WITH OUTPATIENTS: A PRESPECIFIED ANALYSIS OF GALACTIC-HF. Journal of the American College of Cardiology. 79(9). 310–310. 1 indexed citations
18.
Teerlink, John R., Rafael Díaz, G. Michael Felker, et al.. (2020). BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE). Journal of the American College of Cardiology. 75(11). 754–754. 2 indexed citations
19.
Greene, Stephen J., Aldo P. Maggioni, Gregg C. Fonarow, et al.. (2015). Clinical Profile and Prognostic Significance of Natriuretic Peptide Trajectory Following Hospitalization for Worsening Chronic Heart Failure: Findings from the ASTRONAUT Trial. European Journal of Heart Failure. 17(1). 98–108. 28 indexed citations
20.
Greene, Stephen J., Gregg C. Fonarow, Scott Solomon, et al.. (2015). Global Variation in Clinical Profile, Management, and Post-Discharge Outcomes Among Patients Hospitalized For Worsening Chronic Heart Failure: Findings from the ASTRONAUT trial. European Journal of Heart Failure. 17(6). 591–600. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Prastaro Breakdown of academic impact, for papers by Lucia Ilaria Birtolo Breakdown of academic impact, for papers by Evelyn Santiago‐Vacas Breakdown of academic impact, for papers by Ivan Milinković Breakdown of academic impact, for papers by Roberto Spoladore Breakdown of academic impact, for papers by Isabella Evangelista Breakdown of academic impact, for papers by Georgios Efstratiadis Breakdown of academic impact, for papers by Yingying Li Breakdown of academic impact, for papers by Javier E. Banchs Breakdown of academic impact, for papers by Nikolaos Stalikas
Rankless by CCL
2026